Current Infectious Disease Reports

, Volume 15, Issue 3, pp 232–235

Penicillin Failure in the Treatment of Streptococcal Pharyngo-Tonsillitis

Pediatric Infectious Diseases (I Brook, Section Editor)

Abstract

The inadequate penetration of penicillins into the tonsillar tissues and tonsillar surface fluid and microbiologic interactions between Group A beta-hemolytic streptococci (GABHS) and other pharyngo-tonsillar bacterial flora can account for their failure in eradicating GABHS pharyngo-tonsillitis (PT). These interactions include the presence of beta-lactamase producing bacteria (BLPB) that “shield” GABHS from penicillins, the absence of bacteria that interfere with the growth of GABHS, and the coaggregation between GABHS and Moraxella catarrhalis. In the treatment of acute tonsillitis, the use of cephalosporins can overcome these interactions by eradicating aerobic BLPB, while preserving the potentially interfering organisms and eliminating GABHS. In treatment of recurrent and chronic PT, the administration of clindamycin or amoxicillin-clavulanatecan eradicates both aerobic and anaerobic BLPB, as well as GABHS.

Keywords

Tonsillitis Group A streptococci Penicillin Interference Cephalosporins Clindamycin Beta-lactamase 

References

  1. 1.
    Pichichero ME, Casey JR. The evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitis. Diagn Microbiol Infect Dis. 2007;57(Supplement):S39–45.Google Scholar
  2. 2.
    Kaplan EL, Chatwal GS, Rohde M. Reduced ability of penicillin to eradicate ingested Group A streptococci from epithelial cells: clinical and pathogenetic implications. Clin Infect Dis. 2006;43:1398–406.PubMedCrossRefGoogle Scholar
  3. 3.
    Brook I. Role of beta-lactamase–producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis. 1984;6:601–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Lafontaine ER, Wall D, Vanlerberg SL, Donabedian H, Sledjeski DD. Moraxella catarrhalis coaggregates with Streptococcus pyogenes and modulates interactions of S pyogenes with human epithelial cells. Infect Immun. 2004;72:6689–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Grahn E, Holm SE. Bacterial interference in the throat flora during a pharyngo- tonsillitis outbreak in an apartment house area. Zbl Bakl Hyg A. 1983;256:72–9.Google Scholar
  6. 6.
    Brook I. The role of bacterial interference in otitis, sinusitis and tonsillitis. Otolaryngol Head Neck Surg. 2005;133(1):139–46.Google Scholar
  7. 7.
    Neeman R, Keller N, Barzilai A, Korenman Z, Sela S. Prevalence of internalization-associated gene, prtF1, among persisting group-A streptococcus strains isolated from asymptomatic carriers. Lancet. 1998;352:1974–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Stjernquist-Desatnik A, Samuelsson P, Walder M. Penetration of penicillin V to tonsillar surface fluid in healthy individuals and in patients with acute tonsillitis. J Laryngol Otol. 1993;107:309–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Marouni MJ, Barzilai A, Keller N, Rubinstein E, Sela S. Intracellular survival of persistent Group A streptococci in cultured epithelial cells. Int J Med Microbiol. 2004;294:27–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Orrling A, Kamme C, Stjernquist-Desatnik A. Penicillin V, loracarbef and clindamycin in tonsillar surface fluid during acute Group A streptococcal pharyngotonsillitis. Scand J Infect Dis. 2005;37:429–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Brook I. Emergence and persistence of beta-lactamase–producing bacteria in the oropharynx following penicillin treatment. Arch Otolaryngol Head Neck Surg. 1988;114:667–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Brook I. Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate Group A strepharyngo-tonsillitisococci. Pediatr Infect Dis. 1985;4:491–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Brook I, Gober AE. Failure to eradicate streptococci and beta-lactamase producing bacteria. Acta Paediatr. 2008;96:193–5.CrossRefGoogle Scholar
  14. 14.
    Brook I, Yocum P, Friedman EM. Aerobic and anaerobic bacteria in tonsils of children with recurrent tonsillitis. Ann Otol Rhinol Laryngol. 1981;90:261–3.PubMedGoogle Scholar
  15. 15.
    Taylan I, Ozcan I, Mumcuoğlu I, Baran I, Murat Özcan K, Akdoğan O, et al. Comparison of the surface and core bacteria in tonsillar and adenoid tissue with beta-lactamase production. Indian J Otolaryngol Head Neck Surg. 2011;63:223–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Reilly S, Timmis P, Beeden AG, Willis AT. Possible role of the anaerobe in tonsillitis. J Clin Pathol. 1981;34:542–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Tuner K, Nord CE. Beta-lactamase–producing anaerobic bacteria in recurrent tonsillitis. J Antimicrob Chemother. 1982;10(suppl A):153–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Chagollan J, Macias JR, Gil JS. Flora indigena de las amigdales. Invest Med Int. 1984;11:36–9.Google Scholar
  19. 19.
    Kielmovitch IH, Keleti G, Bluestone CD, Wald ER, Gonzales C. Microbiology of obstructive tonsillar hypertrophy and recurrent tonsillitis. Arch Otolaryngol Head Neck Surg. 1989;115:721–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Brook I, Yocum P, Foote Jr PA. Changes in the core tonsillar bacteriology of recurrent tonsillitis, 1977–1993. Clin Infect Dis. 1995;21:171–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Brook I, Yocum P. Quantitative measurement of beta-lactamase level in tonsils of children with recurrent tonsillitis. Acta Otolaryngol Scand. 1984;98:446–60.Google Scholar
  22. 22.
    Brook I. Beta-lactamase-producing bacteria and their role in infection. Rev Med Microbiol. 2005;16:91–9.CrossRefGoogle Scholar
  23. 23.
    Brook I. Treatment of patients with acute recurrent tonsillitis due to Group A beta-haemolytic streptococci: a prospective randomized study comparing penicillin and amoxicillin/clavulanate potassium. J Antimicrob Chemother. 1989;24:227–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaplan EL, Johnson DR. Eradication of Group A streptococci from the upper respiratory tract by amoxicillin with clavulanate after oral penicillin V treatment failure. J Pediatr. 1988;113:400–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Holm S, Henning C, Grahn E, Lomberg H, Staley H. Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethylpenicillin in children. The Swedish Study Group. Scand J Infect Dis. 1995;27:221–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Holm SE, Roos K, Stromberg A. A randomized study of treatment of streptococcal pharyngotonsillitis with cefadroxil or phenoxymethylpenicillin (penicillin V). Pediatr Infect Dis J. 1991;10:S68–71.PubMedCrossRefGoogle Scholar
  27. 27.
    Socransky SS, Manganiello SD. The oral microflora of man from birth to senility. J Periodontol. 1971;42:485–96.PubMedCrossRefGoogle Scholar
  28. 28.
    Brook I, Gober AE. Role of bacterial interference and beta-lactamase-producing bacteria in the failure of penicillin to eradicate Group A streptococcal pharyngotonsillitis. Arch Otolaryngol Head Neck Surg. 1995;121:1405–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Brook I. The role of bacterial interference in otitis, sinusitis and tonsillitis. Otolaryngol Head Neck Surg. 2005;133:139–46.PubMedCrossRefGoogle Scholar
  30. 30.
    Brook I, Gober AE. Bacterial interference by aerobic and anaerobic bacteria in children with recurrent Group A beta-hemolytic streptococcal tonsillitis. Arch Otolaryngol Head Neck Surg. 1999;125:552–4.PubMedGoogle Scholar
  31. 31.
    Roos K, Grahn E, Holm SE, Johansson H, Lind L. Interfering alpha- streptococci as a protection against recurrent streptococcal tonsillitis in children. Int J Pediatr Otol. 1993;25:141–8.CrossRefGoogle Scholar
  32. 32.
    Roos K, Holm SE, Grahn E, Lind L. Alpha-strepharyngo-tonsillitisococci as supplementary treatment of recurrent pharyngo-tonsillitis: a randomized placebo-controlled study. Scand J Infect Dis. 1993;25:31–5.PubMedGoogle Scholar
  33. 33.
    Roos K, Holm SE, Grahn-Hakansson E, Lagergren L. Recolonization with selected alpha- streptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis – a randomized placebo-controlled multicentre study. Scand J Infect Dis. 1996;28:459–62.PubMedCrossRefGoogle Scholar
  34. 34.
    Falck G, Grahn-Håkansson E, Holm SE, Roos K, Lagergren L. Tolerance and efficacy of interfering alpha- streptococcus in recurrence of streptococcal pharyngotonsillitis: a placebo-controlled study. Acta Otolaryngol (Stockh). 1999;119:944–8.CrossRefGoogle Scholar
  35. 35.
    Brook I, Gober AE. Long-term effects on the nasopharyngeal flora of children following antimicrobial therapy of acute otitis media with cefdinir or amoxicillin-clavulanate. J Med Microbiol. 2005;54:553–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Brook I, Gillmore JD. Evaluation of bacterial interference and beta-lactamase production in management of experimental infection with Group A beta-hemolytic streptococcus. Antimicrob Agents Chemother. 1993;37:1452–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Brook I, Gober E. Recovery of interfering and beta-lactamase-producing bacteria from group A beta-haemolytic streptococci carriers and non-carriers. J Med Microbiol. 2006;55:1741–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Brook I, Gillmore JD. Enhancement of growth of Group A beta-hemolytic streptococcus in mixed infections with aerobic and anaerobic bacteria. Clin Microbiol Infect. 1996;1:179–82.PubMedCrossRefGoogle Scholar
  39. 39.
    Brook I, Gober AE. Increased recovery of Moraxella catarrhalis and Haemophillus influenzae in association with Group A beta-hemolytic streptococcus in healthy children and those with pharyngo-tonsillitis. J Med Microb. 2006;55:989–92.CrossRefGoogle Scholar
  40. 40.
    Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of Group A streptococcal tonsillopharyngitis in adults. Clin Infect Dis. 2004;38:1526–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? Pediatr Infect Dis J. 1993;12:268–74.PubMedCrossRefGoogle Scholar
  42. 42.
    Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Practice guidelines for the diagnosis and management of Group A streptococcal pharyngitis. 2012 update of the Infectious Diseases Society of America. Clin Infect Dis. 2012;55:1279–82.PubMedCrossRefGoogle Scholar
  43. 43.
    Brook I, Hirokawa R. Treatment of patients with a history of recurrent tonsillitis due to Group A beta-hemolytic streptococci. A prospective randomized study comparing penicillin, erythromycin and clindamycin. Clin Pediatr. 1985;24:331–6.CrossRefGoogle Scholar
  44. 44.
    Casey JR, Pichichero ME. Meta-analysis of short course antibiotic treatment for Group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 2005;24:909–17.PubMedCrossRefGoogle Scholar
  45. 45.
    Brook I, Gober AE. Rate of eradication of Group A beta-hemolytic streptococci in children with pharyngo-tonsillitis by amoxicillin and cefdinir. Int J Pediatr Otolaryngol. 2009;757–9.Google Scholar
  46. 46.
    Brook I, Foote PA. Efficacy of penicillin versus cefdinir in eradication of Group A streptococcal pharyngo-tonsillitis and tonsillar flora. Antimicrob Agents Chemother. 2005;49:4787–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Breese BB, Disney FA, Talpey WB. Beta-hemolytic streptococcal illness: comparison of lincomycin, ampicillin, and potassium penicillin in treatment. Am J Dis Child. 1966;112:21–7.PubMedGoogle Scholar
  48. 48.
    Breese BB, Disney FA, Talpey WB, Green J. Beta-hemolytic streptococcal infection: comparison of penicillin and lincomycin in the treatment of recurrent infections of the carrier state. Am J Dis Child. 1969;117:14–527.Google Scholar
  49. 49.
    Randolph MF, DeHaan RM. A comparison of lincomycin and pencillin in the treatment of Group A streptococcal infection. Del Med J. 1969;41:51–62.PubMedGoogle Scholar
  50. 50.
    Howie VM, Plousard JH. Treatment of group A streptococcal pharyngitis in children: comparison of lincomycin and penicillin G given orally and benzathine penicillin G given intramuscularly. Am J Dis Child. 1971;121:477–80.PubMedGoogle Scholar
  51. 51.
    Randolph MF, Redys JJ, Hibbard EW. Streptococcal pharyngitis: III. Streptococcal recurrence rates following therapy with penicillin or with clindamycin (7-chlorolincomycin). Del Med J. 1970;42:87–92.PubMedGoogle Scholar
  52. 52.
    Stillerman M, Isenberg HD, Facklam RR. Streptococcal pharyngitis therapy: comparison of clindamycin palmitate and potassium phenoxymethyl penicillin. Antimicrob Agents Chemother. 1973;4:514–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Chaudhary S, Bilinsky SA, Hennessy JL, Soler SM, Wallace SE, Schacht CM, et al. Penicillin V and rifampin for the treatment of Group A streptococcal pharyngitis: a randomized trial of 10 days penicillin vs 10 days penicillin with rifampin during the final 4 days of therapy. J Pediatr. 1985;106:481–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Smith TD, Huskins WC, Kim KS, Kaplan EL. Efficacy of beta-lactamase-resistant penicillin and influence of penicillin in eradicating streptococci for the pharynx after failure of penicillin therapy for Group A streptococcal pharyngitis. J Pediatr. 1987;110:777–82.PubMedCrossRefGoogle Scholar
  55. 55.
    Orrling A, Stjernquist-Desatnik A, Schalen C, Kamme C. Clindamycin in persisting streptococcal pharyngotonsillitis after penicillin treatment. Scand J Infect Dis. 1994;26:535–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Mahakit P, Vicente JG, Butt DI, Angeli G, Bansal S, Zambrano D. Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years. Clin Ther. 2006;28:99–109.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Pediatrics and MedicineGeorgetown University School of MedicineWashingtonUSA

Personalised recommendations